

Dr. Katy Rezvani was recruited to MD Anderson in 2012 as Professor of Medicine, Director of Translational Research and Medical Director of the GMP Facility. She was appointed Chief of the Section for Cellular Therapy in the Department of Stem Cell Transplantation in 2017. She is the Principal Investigator on numerous grants and trials. Dr. Rezvani is Specialty Chief Editor for the section of Cancer Immunity and Immunotherapy for *Frontiers in Immunology* and an Associate Editor for *Cytotherapy*. She has over 150 peer-reviewed publications related to Immunotherapy, Cellular Therapy and Hematology/Oncology and hematopoietic transplantation. She is on the Center for International Blood and Marrow Transplant (CIBMTR) clinical trials advisory committee, a member of the BMT CTN Cell and Gene Therapy and has served on the organizing committees of the Society for Natural Immunity, International Society of Cell Therapy and Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR. Dr. Rezvani serves on the Clinical Oncology (CONC) NIH Study Section and is a reviewer for the Leukemia Lymphoma Society, Cancer research UK, The Medical Research Council UK, the Dutch Cancer Society and the Kay Kendall Leukemia Fund. Dr. Rezvani has an active research laboratory program in tumor immunology where the focus of her research group is to study the role of natural killer cells (NK) cells in mediating immunity against hematologic disorders as well as solid tumors, and to understand the mechanisms of tumor-induced NK cell dysfunction. The goal of these studies is to develop strategies to enhance NK cell effector function against tumors by genetically engineering the cells to enhance their in vivo antileukemic activity and persistence. Dr. Rezvani's research interests also involve using cytotoxic T cells (CTL) to treat viral and malignant diseases. She is the recipient of multiple grants and awards, including two RO1s from the National Cancer Institute, two Leukemia Lymphoma Society Translational Research Program, two CLL Global Awards to study T and NK cells defects in CLL, a Research Scholar Grant from the American Cancer Society and a number of foundation awards. Her laboratory program in transplant immunology has led to the approval and funding of a number of Phase I/II studies of immunotherapy in patients with hematologic malignancies and solid tumors, as well as the first-in-human clinical trial of off-the-shelf CAR-transduced cord blood NK cells in patients with relapsed/refractory lymphoid malignancies.